ePrivacy and GPDR Cookie Consent management by TermsFeed Privacy Generator
PartnerPhoto

SenzaGen

SenzaGen State-of-the-art non-animal tests for assessing a substance’s allergenicity


SenzaGen is a Swedish biotech company that provides state-of-the-art non-animal tests for assessing a substance’s allergenicity. The GARD® test method combines genomic data from human cells with machine learning for a unique capability to identify and analyze whether a chemical could cause allergic reactions on the skin or in the respiratory tract. With excellent predictivity, GARD® meets needs in several industries and helps companies develop, produce and deliver safer, ethical and more sustainable products. The GARD® tests are performed in SenzaGen’s GLP-approved lab and by selected partners in Europe and the US. SenzaGen has its headquarters in Lund, Sweden and a subsidiary in the US.

For more information, please visit: www.senzagen.com

GARDskin

GARDskin is a robust in vitro test to identify potential chemical skin sensitizers with broad applicability and over 90% prediction accuracy.

GARDpotency

GARDpotency is an in vitro add-on test to GARDskin for potency classification according to GHS/CLP.

GARDskin Dose-Response

GARDskin Dose-Response is an in vitro test for quantitative skin sensitizing potency assessment of chemicals, adapted from GARDskin.

SaferWorldbyDesign

SaferWorldbyDesign integrates in silico and in vitro methods to develop standard and premium Integrated Approaches to Testing and Assessment (IATAs), including methods that support ingredient and formulation screening and testing, product design and the preparation of Regulatory Dossiers.

Disclaimer

Edelweiss Connect GmbH is registered as a limited company with Handelsregisteramt of Kanton Basel-Stadt

Swiss ID (UID) number: CHE-114.414.615

Copyright | SaferWorldbyDesign 2022